Comparison and evaluation of DRI® methamphetamine, DRI ecstasy, abuscreen® ONLINE amphetamine, and a modified abuscreen ONLINE amphetamine screening immunoassays for the detection of amphetamine (AMP), methamphetamine (MTH), 3,4-methylenedioxyamphetamine (MDA), and 3,4-methylenedioxymethamphetamine (MDMA) in human urine

Journal of Analytical Toxicology

Volumn 27, Issue 5, 2003, Pages 265-269

  Stout, Peter R ^a   Klette, Kevin L ^b   Wiegand, Russell ^b  

^a Aegis Sciences Corporation   (United States)

^b Navy Drug Screening Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; METHAMPHETAMINE; REAGENT;

ACCURACY; ARTICLE; CALIBRATION; DEVICE; EVALUATION; GAS CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MASS SPECTROMETRY; PERFORMANCE; REFERENCE VALUE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STANDARD; URINALYSIS;

EID: 0037623886     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/27.5.265     Document Type: Article

References (16)

1. J. Cloud. What ecstasy does to your brain. Time, June 5, 2000.
2. D. Castellon. Most ecstasy test results wrong in Jan. field trial. Air Force Times, April 25, 2002.
3. C. Munsey. Ecstasy test sinks after flood of false positives. Navy Times, April 22, 2002.
4. A. Sabar. Overly sensitive test fouls military's war on ecstasy. Baltimore Sun, March 14, 2002
5. S. Jones. DOD study indicates major drop in drug use. Stars and Stripes, May 15, 2002.
6. H. Zhao, R. Brenneisen, A. Scholer, A.J. McNally, M.A. ElSohly, T.P. Murphy, and S.J. Salamone. Profiles of urine samples taken from ecstasy users at rave parties: analysis by immunoassays, HPLC and GC-MS. J. Anal. Toxicol. 25: 258-269 (2001).
7. B.K. Logan. Amphetamines: an update on forensic issues. J. Anal. Toxicol. 25: 400-404 (2001).
8. J. D'Nicuola, R. Jones, B. Levine, and M.L. Smith. Evaluation of six commercial amphetamine and methamphetamine immunoassays for cross-reactivity to phenylpropanolamine and ephedrine in urine. J. Anal. Toxicol. 16: 211-213 (1992).
9. P. Kintz and C. Giroud. Immunoassay responses of MBDB. J. Anal. Toxicol. 21: 589-590 (1997).
10. D.P. Baker, M.S. Murphy, P.F. Shepp, V.R. Royo, M.E. Caldarone, B. Escoto, and S.J. Salamone. Evaluation of the Abuscreen® ONLINE assay for amphetamines on the Hitachi 737: comparison with EMIT and GC/MS methods. J. Forensic Sci. 40: 108-112 (1995).
11. V. Lekskulchai and C. Mokkhavesa. Evaluation of Roche Abuscreen® ONLINE amphetamine immunoassay for screening of new amphetamine analogues. J. Anal. Toxicol. 25: 471-475 (2001).
12. L.A. Broussard and L. Hanson. Evaluation of DRI® enzyme immunoassays for drugs of abuse screening on the Cobas Mira. Clin. Lab. Sci. 10: 83-86 (1997).
13. P.R. Stout, C.K. Horn, and K.L. Klette. Rapid simultaneous determination of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-MDMA, and MDEA in urine by solid phase extraction and GC-MS: a method optimized for high volume laboratories. J. Anal Toxicol. 26: 253-261 (2002).
14. H.M. Blanck, L.K. Khan, and M.K. Serudula. Use of nonprescription weight loss products: results from a multistate survey. J. Am. Med. Assoc. 286: 930-935 (2001).
15. B.J. Gurley, S.F. Gardner, L.M. White, and P.L. Wang. Ephedrine pharmacokinetics after ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther. Drug Monit. 20: 439-445 (1998).
16. B.J. Gurley, S.F. Gardner, and M.A. Hubbard. Content versus label claims in ephedra-containing dietary supplements. Am. J. Health Syst. Pharm. 57: 963-969 (2000).